Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung

Endocrine-Related Cancer

Volumn 17, Issue 4, 2010, Pages 977-987

  Righi, Luisella ^a   Volante, Marco ^a   Rapa, Ida ^a   Tavaglione, Veronica ^a   Inzani, Frediano ^b   Pelosi, Giuseppe ^c   Papotti, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; S6 KINASE; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOID; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; RECURRENT CANCER; SMALL CELL CARCINOMA; WESTERN BLOTTING;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 78649893061     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0157     Document Type: Article

References (41)

1. Bjornsti MA & Houghton PJ 2004 The TOR pathway: a target for cancer therapy. Nature Reviews. Cancer 4 335-348. (doi:10.1038/nrc1362)
2. Campbell L, Jasani B, Edwards K, Gumbleton M & Griffiths DF 2008 Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. British Journal of Cancer 98 931-940. (doi:10.1038/sj.bjc.6604243)
3. Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV & Papotti M 2008 Prognostic role of osteopontin expression in malignant pleural mesothelioma. American Journal of Clinical Pathology 130 58-64. (doi:10.1309/TWCQV536W WRNEU51)
4. Dancey JE 2006 Therapeutic targets: mTOR and related pathways. Cancer Biology & Therapy 5 1065-1073.
5. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J et al. 2006 A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer 95 1148-1154. (doi:10.1038/sj.bjc.6603419)
6. Duran I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, Yao J & Tabernero J 2007 New drug development in digestive neuroendocrine tumors. Annals of Oncology 18 1307-1313. (doi:10.1093/annonc/mdm009)
7. Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L & Susini C 2000 Signal transduction of somatostatin receptors negatively controlling cell proliferation. Journal of Physiology 94 205-210. (doi:10. 1016/S0928-4257(00)00206-0)
8. Garcia-Yuste M, Matilla JM & Gonzalez-Aragoneses F 2008 Neuroendocrine tumors of the lung. Current Opinion in Oncology 20 148-154. (doi:10.1097/CCO. 0b013e3282f35ed3)
9. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, Salahuddin N, Korbonits M & Grossman AB 2008 Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt - mTOR - p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 87 168-181. (doi:10.1159/000111501)
10. Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB & Shimon I 2010 The rapamycinderivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt - mTOR - p70S6K pathway in human medullary thyroid carcinoma cells. Molecular and Cellular Endocrinology 315 87-94. (doi:10.1016/j.mce.2009.09.027)
11. Guertin DA & Sabatini DM 2007 Defining the role of mTOR in cancer. Cancer Cell 12 9-22. (doi:10.1016/j.ccr.2007.05.008)
12. Heesom KJ, Gampel A, Mellor H & Denton RM 2001 Cell cycle-dependent phosphorylation of the translational repressor eIF-4E binding protein-1 (4E-BP1). Current Biology 11 1374-1379. (doi:10.1016/S0960-9822(01)00422-5)
13. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R & Filipits M 2007 Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clinical Cancer Research 13 4795-4799. (doi:10.1158/1078-0432.CCR-07-0738)
14. Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE & Chung LW 2005 Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Research 65 2303-2313. (doi:10.1158/0008- 5472.CAN-04-3448)
15. Kulke MH 2007 New developments in the treatment of gastrointestinal neuroendocrine tumors. Current Oncology Reports 9 177-183. (doi:10.1007/s11912- 007-0019-y)
16. Lam JS, Pantuck AJ, Belldegrun AS & Figlin RA 2007 Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clinical Cancer Research 13 703s-708s. (doi:10.1158/ 1078-0432.CCR-06-1864)
17. Meric-Bernstam F & Gonzalez-Angulo AM 2009 Targeting the mTOR signaling network for cancer therapy. Journal of Clinical Oncology 27 2278-2287. (doi:10. 1200/JCO.2008.20.0766)
18. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G et al. 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT - mTOR pathway. Journal of Clinical Oncology 28 245-255. (doi:10.1200/JCO.2008.21.5988)
19. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T et al. 2008 Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. Journal of Clinical Oncology 26 361-367. (doi:10.1200/JCO.2007.12. 0345)
20. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC & Meric-Bernstam F 2008 Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocrine-Related Cancer 15 257-266. (doi:10.1677/ERC-07-0202)
21. Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM & Paik NS 2008 Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Research and Treatment 110 477-483. (doi:10.1007/s10549-007-9746-x)
22. Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Roske A, Sehouli J, Dietel M & Denkert C 2008 Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncology Reports 20 1409-1417. (doi:10. 3892/or-00000160)
23. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH & Johnson DH 2007 A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). Journal of Thoracic Oncology 2 1036-1041. (doi:10.1097/JTO.0b013e318155a439)
24. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS & Figlin RA 2007 Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109 2257-2267. (doi:10.1002/cncr.22677)
25. Pelosi G, Volante M, Papotti M, Sonzogni A, Masullo M & Viale G 2006 Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging 50 272-287. (Pubitemid 46157609)
26. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J et al. 2001 An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PtenC/K mice. PNAS 98 10320-10325. (doi:10.1073/pnas.171060098)
27. Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G & Papotti M 2010 Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 "clinically aggressive" cases. Annals of Oncology 21 548-555. (doi:10.1093/annonc/mdp334)
28. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP & Caplin ME 2006 Epidermal growth factor receptor expression and activation in neuroendocrine tumours. Journal of Neuroendocrinology 18 355-360. (doi:10. 1111/j.1365-2826. 2006.01425.x)
29. Shida T, Kishimoto T, Furuya M, Nikaido T, Koda K, Takano S, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M et al. 2010 Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemotherapy and Pharmacology 65 889-893. (doi:10.1007/s00280- 009-1094-6)
30. Srirajaskanthan R, Toumpanakis C, Karpathakis A, Marelli L, Quigley AM, Dusmet M, Meyer T & Caplin ME 2009 Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung Cancer 65 68-73. (doi:10.1016/ j.lungcan.2008.10.025)
31. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U & Stalla GK 2006 Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Research 66 1576-1582. (doi:10.1158/0008-5472.CAN-05-1189)
32. Travis WD, Brambilla E, Muller-Hermelink HK & Harris CC 2004 Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press.
33. Vignot S, Faivre S, Aguirre D & Raymond E 2005 mTOR-targeted therapy of cancer with rapamycin derivatives. Annals of Oncology 16 525-537. (doi:10.1093/annonc/mdi113)
34. Wang L, Ignat A & Axiotis CA 2002 Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Applied Immunohistochemistry & Molecular Morphology 10 139-146. (doi:10.1097/00022744-200206000-00008) (Pubitemid 34553170)
35. Wang X, Li W, Parra JL, Beugnet A & Proud CG 2003 The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Molecular and Cellular Biology 23 1546-1557. (doi:10.1128/MCB.23.5.1546-1557.2003)
36. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G & Seufferlein T 2000 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research 60 4573-4581.
37. Yao JC 2007 Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Practice & Research. Clinical Endocrinology & Metabolism 21 163-172. (doi:10.1016/j.beem.2007.01.006)
38. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A et al. 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology 26 4311-4318. (doi:10.1200/JCO.2008.16.7858)
39. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69-76. (doi:10.1200/JCO.2009.24.2669)
40. Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G et al. 2010 Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocrine-Related Cancer 17 719-729. (doi:10.1677/ERC-10-0097)
41. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH & Auernhammer CJ 2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85 54-60. (doi:10.1159/000100057)